TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28084155

Group type: EXPERIMENTAL
Intervention: MIS-TLIF
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conventional TLIF
Number of subjects: 106
Study: 26629174

Group type: EXPERIMENTAL
Intervention: Moxibustion with Chinese herbal
Number of subjects: 355

Group type: COMPARATOR
Intervention: Loratadine
Number of subjects: 355
Study: 23710718

Group type: EXPERIMENTAL
Intervention: Negative pressure therapy (NPT)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Traditional occlusive dressing method (Control)
Number of subjects: 307
Study: 21443557

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) procedure combined with orthodontic button application (CAF+B)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Coronally advanced flap (CAF) procedure (Control group)
Number of subjects: 41
Study: 18614981

Group type: EXPERIMENTAL
Intervention: Drug-eluting stent (DES) implantation
Number of subjects: 198
Study: 16641576

Group type: EXPERIMENTAL
Intervention: Pantoprazole 10 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 53
Study: 14615736

Group type: EXPERIMENTAL
Intervention: Home-visiting intervention with weekly visits by paraprofessionals for the first 8 weeks of life
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (LBW-T infants without intervention)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: LBW-T intervened infants
Number of subjects: 140
Study: 10632407

Group type: EXPERIMENTAL
Intervention: 75 IU of FSH
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 150 IU of FSH
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no FSH treatment)
Number of subjects: 40
Study: 9010698

Group type: EXPERIMENTAL
Intervention: Imipramine (75 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Entacapone (200 mg) and Imipramine (75 mg) in combination
Number of subjects: 12

Group type: COMPARATOR
Intervention: Entacapone (200 mg)
Number of subjects: 12
Study: 1561287

Group type: EXPERIMENTAL
Intervention: Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: National Institute of Mental Health Global Obsessive-Compulsive Scale (NIMH-GOCS)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: SCL-90-Obsessive-Compulsive Subscale (SCL-90-OCS)
Number of subjects: 23
Study: 3881105

Group type: EXPERIMENTAL
Intervention: labetalol 480 mg/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 31356985

Group type: EXPERIMENTAL
Intervention: Active (a) tDCS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham (s) tDCS
Number of subjects: 20
Study: 28490581

Group type: EXPERIMENTAL
Intervention: Four-valent HPV vaccine
Number of subjects: 388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study: 27812717

Group type: EXPERIMENTAL
Intervention: EFV/FTC/TDF
Number of subjects: 35

Group type: COMPARATOR
Intervention: RAL/DRV/r
Number of subjects: 35
Study: 24628705

Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Maintenance CST (MCST)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 85
Study: 22713768

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) initiated in 97 children
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Baseline selenium (Se) levels
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Baseline zinc (Zn) levels
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Pre-ART zinc levels
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Baseline CD4%
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Baseline HIV-RNA
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Baseline ferritin
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 141
Study: 20404773

Group type: EXPERIMENTAL
Intervention: Health Empowerment Intervention (HEI)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Weekly newsletter (comparison group)
Number of subjects: 59
Study: 18523223

Group type: EXPERIMENTAL
Intervention: Registered RCTs measuring patient-important outcomes
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Registered RCTs measuring physiological and laboratory outcomes
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Registered RCTs measuring surrogate outcomes
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Registered RCTs measuring patient-important outcomes as primary or secondary outcomes
Number of subjects: 436
Study: 15902161

Group type: EXPERIMENTAL
Intervention: Active ExMI treatment
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham ExMI treatment
Number of subjects: 51
Study: 14522571

Group type: EXPERIMENTAL
Intervention: PBMCs from FH patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FH serum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control serum
Number of subjects: 0
Study: 10903043

Group type: EXPERIMENTAL
Intervention: Partial middle turbinate resection
Number of subjects: 1106

Group type: COMPARATOR
Intervention: No partial middle turbinate resection
Number of subjects: 1106
Study: 9131395

Group type: EXPERIMENTAL
Intervention: Ribavirin (800 mg/day for 2 months) + Interferon (9 Mu/week for 6 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Interferon (9 Mu/week for 6 months)
Number of subjects: 20
Study: 1540493

Group type: EXPERIMENTAL
Intervention: Information provided by an academic representative during a short 'sales' interview.
Number of subjects: 101
Study: 6374057

Group type: EXPERIMENTAL
Intervention: CAF (cyclophosphamide, doxorubicin, and 5-fluorouracil)
Number of subjects: 187

Group type: COMPARATOR
Intervention: CAF + CAMELEON (CAF alternating with cytosine arabinoside, methotrexate with leucovorin rescue, and oncovin)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: CAF
Number of subjects: 187

Group type: COMPARATOR
Intervention: CAMELEON
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: CAF-CAMELEON regimen
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: CAF-CAMELEON
Number of subjects: 187
Study: 31587724

Group type: EXPERIMENTAL
Intervention: Balanced anesthetic technique with EEG guidance
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 88
Study: 29489921

Group type: EXPERIMENTAL
Intervention: Structured safety huddle review of alarm data with discussions to reduce alarms
Number of subjects: 11308

Group type: COMPARATOR
Intervention: Control units (no intervention)
Number of subjects: 11308
Study: 26820762

Group type: EXPERIMENTAL
Intervention: Parents with VLBW infants
Number of subjects: 403

Group type: COMPARATOR
Intervention: Parents with term infants
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 403
Study: 25448437

Group type: COMPARATOR
Intervention: Control group (Gp 1) - one-off oral health education talk to parents
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Gp 2 - oral health education talk and parental toothbrushing training, reinforced every 6 months
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Gp 3 - semi-annual application of fluoride varnish in addition to Gp 2 intervention
Number of subjects: 450
Study: 22252363

Group type: EXPERIMENTAL
Intervention: 8% poultry offal meal (OM) diet from 1 to 42 days
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Vegetable diet (VD) from 1 to 21 days and 8% OM diet from 22 to 42 days
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: VD from 1 to 35 days and 8% OM diet from 36 to 42 days
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: 8% OM diet from 1 to 21 days and VD from 22 to 42 days
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: 8% OM diet from 1 to 35 days and VD from 36 to 42 days
Number of subjects: 720

Group type: COMPARATOR
Intervention: Vegetable diet (VD) from 1 to 42 days
Number of subjects: 720
Study: 20380654

Group type: EXPERIMENTAL
Intervention: Initial subcutaneous bolus of 1.4 U
Number of subjects: 10

Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion without initial bolus
Number of subjects: 10
Study: 17666472

Group type: EXPERIMENTAL
Intervention: Cinacalcet hydrochloride (30 mg twice daily to 90 mg four times daily) for 16 weeks
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cinacalcet hydrochloride
Number of subjects: 29
Study: 11069438

Group type: EXPERIMENTAL
Intervention: Propionyl‐L‐carnitine hydrochloride (1 g)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propionyl‐L‐carnitine hydrochloride (8 g)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9308584

Group type: EXPERIMENTAL
Intervention: Prophylactic balloon angioplasty (PTA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 0
Study: 8369579

Group type: EXPERIMENTAL
Intervention: Cyclosporin 5 mg/kg/day
Number of subjects: 76

Group type: COMPARATOR
Intervention: Etretinate 0.75 reduced to 0.5 mg/kg/day
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Cyclosporin maintenance therapy 2.5‐5 mg/kg/day
Number of subjects: 76
Study: 3538936

Group type: EXPERIMENTAL
Intervention: nalbuphine 0.3 mg kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: saline
Number of subjects: 40
Study: 29482397

Group type: EXPERIMENTAL
Intervention: Dual-pulsed 532-nm/1064-nm QS laser treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Single-pulsed 1064-nm Nd:YAG laser treatment
Number of subjects: 10
Study: 27504890

Group type: EXPERIMENTAL
Intervention: 2-hour PIVC online course followed by an 8-hour live training course using simulation tools
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group receiving the same intervention after crossover
Number of subjects: 0
Study: 24304551

Group type: EXPERIMENTAL
Intervention: rosuvastatin (20 mg 12 hours before coronary angiography + 20 mg immediately before PCI)
Number of subjects: 445

Group type: COMPARATOR
Intervention: PCI without statin therapy (control group)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: rosuvastatin (20 mg twice a day)
Number of subjects: 445
Study: 22394023

Group type: EXPERIMENTAL
Intervention: Airborne-particle abraded dowels stored dry
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dowels stored for 24 hours in aqueous solution at 37°C
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Airborne-particle abraded dowels followed by 24-hour aqueous storage at 37°C
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dowels stored for 30 days in aqueous solution at 37°C
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Airborne-particle abraded dowels followed by 30-day aqueous storage at 37°C
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dry control group
Number of subjects: 60
Study: 19706212

Group type: COMPARATOR
Intervention: Iron and folic acid supplements (IFA; 60 mg Fe, 500 microg folic acid)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Leaf concentrate (LC; 5 mg Fe, 13 microg folic acid)
Number of subjects: 102
Study: 18958549

Group type: EXPERIMENTAL
Intervention: FSSG scores in patients with reflux esophagitis
Number of subjects: 470

Group type: COMPARATOR
Intervention: FSSG scores in relation to hiatal hernia presence
Number of subjects: 470

Group type: COMPARATOR
Intervention: FSSG scores in relation to cardiac sphincter laxity (valve factor)
Number of subjects: 470
Study: 15706071

Group type: EXPERIMENTAL
Intervention: Active Ergonomics Training (AET)
Number of subjects: 87
Study: 12535042

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 53

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Sevoflurane and Propofol
Number of subjects: 53
Study: 10759035

Group type: EXPERIMENTAL
Intervention: Peer-delivered educational intervention
Number of subjects: 966

Group type: COMPARATOR
Intervention: Standard HIV testing and counseling protocol
Number of subjects: 966

Group type: EXPERIMENTAL
Intervention: ASPD status
Number of subjects: 966

Group type: EXPERIMENTAL
Intervention: Depression status
Number of subjects: 966
Study: 8947790

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 23
Study: 1379660

Group type: EXPERIMENTAL
Intervention: 10% pentastarch (group P)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 25% albumin (group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (group C)
Number of subjects: 90
Study: 30604047

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 0
Study: 27869293

Group type: EXPERIMENTAL
Intervention: Culturally relevant cancer education program combined with navigation services
Number of subjects: 705

Group type: COMPARATOR
Intervention: General health education including information about cervical cancer risk and screening
Number of subjects: 705
Study: 26483333

Group type: EXPERIMENTAL
Intervention: Crizotinib (250 mg orally twice daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Chemotherapy (docetaxel 75 mg/m2 every three weeks)
Number of subjects: 28
Study: 23672993

Group type: EXPERIMENTAL
Intervention: AHR-guided treatment strategy
Number of subjects: 137

Group type: COMPARATOR
Intervention: Usual care by paediatrician and general practitioner
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: AHR measurement
Number of subjects: 137
Study: 21719901

Group type: EXPERIMENTAL
Intervention: CHO solution (1.2 g CHO/kg body mass)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CHO-PRO solution (1.2 g CHO/kg body mass and 0.4 g PRO/kg body mass)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 12
Study: 19574255

Group type: EXPERIMENTAL
Intervention: FC‐sIPPV
Number of subjects: 10

Group type: COMPARATOR
Intervention: TC‐sIPPV
Number of subjects: 10
Study: 18490279

Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Atenolol-based treatment
Number of subjects: 937
Study: 16020559

Group type: EXPERIMENTAL
Intervention: MR angiography
Number of subjects: 157

Group type: COMPARATOR
Intervention: CT angiography
Number of subjects: 157
Study: 12450926

Group type: EXPERIMENTAL
Intervention: Alteplase for thrombolysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation of thrombolysis
Number of subjects: 0
Study: 10638397

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis using impedance quotients (F2/R), weight, and gestational age as variables.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Weight alone as a predictive model.
Number of subjects: 24
Study: 7490363

Group type: EXPERIMENTAL
Intervention: Daily application of UVA/UVB sunscreen for 24 months
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 46
Study: 1780566

Group type: EXPERIMENTAL
Intervention: Accurate performance information
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: False information that they lifted more than their actual lift
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: False information that they lifted less than their actual lift
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Past weightlifting performance
Number of subjects: 36
Study: 7074241

Group type: EXPERIMENTAL
Intervention: Atropine methonitrate 1.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30418214

Group type: EXPERIMENTAL
Intervention: Hydromorphone (32 mg IV)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Buprenorphine (32 mg IV)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Hydromorphone and Buprenorphine compared with placebo
Number of subjects: 13

Group type: COMPARATOR
Intervention: Hydromorphone
Number of subjects: 13
Study: 28248888

Group type: EXPERIMENTAL
Intervention: Bipolar pulsed radiofrequency (PRF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Monopolar pulsed radiofrequency (PRF)
Number of subjects: 50
Study: 26007260

Group type: EXPERIMENTAL
Intervention: Pylorus Preserving Pancreaticoduodenectomy (PPPD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Whipple's Procedure (SW)
Number of subjects: 0
Study: 23660462

Group type: EXPERIMENTAL
Intervention: HGHH curriculum
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: HGHH curriculum (attending >1 class)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 139
Study: 21843830

Group type: EXPERIMENTAL
Intervention: Home-based exercise program (30 minutes per session, 3 sessions per week for 8 weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual activity (control group)
Number of subjects: 51
Study: 19679578

Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Suppression
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 60
Study: 17852370

Group type: EXPERIMENTAL
Intervention: Blocking vision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocking touch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocking audition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocking olfaction
Number of subjects: 0
Study: 15510361

Group type: EXPERIMENTAL
Intervention: 2.0-mm locking plates
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2.0-mm standard plates
Number of subjects: 90
Study: 11555383

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) at approximately half the microgram dose for 6 months
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) or Budesonide (BUD)
Number of subjects: 133
Study: 9814422

Group type: EXPERIMENTAL
Intervention: Turbo‐FLAIR imaging
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gadolinium‐enhanced imaging
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: T2‐weighted imaging
Number of subjects: 20
Study: 7886393

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg once daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg once daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3126527

Group type: EXPERIMENTAL
Intervention: R 58 735 (5 mg b.i.d. for 2 days followed by 10 mg b.i.d. for 5 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: R 58 735
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29310605

Group type: EXPERIMENTAL
Intervention: Oncologist training and patient communication aid
Number of subjects: 192

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 192
Study: 26856694

Group type: EXPERIMENTAL
Intervention: Emollient followed by topical corticosteroids (TCS) applied 15 minutes later, twice daily for 2 weeks.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Topical corticosteroids (TCS) followed by emollient applied 15 minutes later, twice daily for 2 weeks.
Number of subjects: 46
Study: 25555191

Group type: EXPERIMENTAL
Intervention: 50% dose of verteporfin (PDT)
Number of subjects: 131

Group type: COMPARATOR
Intervention: 30% dose of verteporfin (PDT)
Number of subjects: 131
Study: 24004887

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1500 mg Ca/d)
Number of subjects: 525

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 525
Study: 20186620

Group type: EXPERIMENTAL
Intervention: Modified D(2) radical total gastrectomy with spleen-preserving
Number of subjects: 112

Group type: COMPARATOR
Intervention: D(2) radical total gastrectomy with splenectomy
Number of subjects: 112
Study: 18280877

Group type: EXPERIMENTAL
Intervention: Antepartum and intrapartum predictors for uterine rupture
Number of subjects: 0
Study: 15649575

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention group (n=102)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Standard intervention group (control group, n=356)
Number of subjects: 458
Study: 12127125

Group type: EXPERIMENTAL
Intervention: Carbon dioxide pneumoperitoneum (CLC, n = 26)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Gasless pneumoperitoneum (GLC, n = 24)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (GLC and CLC)
Number of subjects: 50
Study: 10334416

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (300 IU/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol
Number of subjects: 40
Study: 7503614

Group type: EXPERIMENTAL
Intervention: Lisinopril (5 mg/day as a starting dose followed by 5 mg at the 24th hour and then 10 mg/day)
Number of subjects: 19394

Group type: COMPARATOR
Intervention: Control group (no lisinopril)
Number of subjects: 19394

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 19394

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate
Number of subjects: 19394

Group type: COMPARATOR
Intervention: Control group (no glyceryl trinitrate)
Number of subjects: 19394
Study: 1958425

Group type: EXPERIMENTAL
Intervention: Exosurf Neonatal (synthetic surfactant)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 218
Study: 7180065

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (1.5 g)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 29698772

Group type: EXPERIMENTAL
Intervention: PACT Intensive Management (PIM) teams
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care through PACT
Number of subjects: 0
Study: 24756172

Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training (CCT) using the AttenFocus program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group with a simple, non-hierarchical version of CCT
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training (CCT)
Number of subjects: 60
Study: 26111129

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative therapy (OMTh) provided 4 times at intervals of 2 weeks.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Waitlist control group (no OMTh during the 8-week study).
Number of subjects: 80
Study: 23577552

Group type: EXPERIMENTAL
Intervention: Alkalinized 2% lidocaine/epinephrine 1:100,000 at pH 7.31
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-alkalinized 2% lidocaine/epinephrine 1:100,000 at pH 3.85
Number of subjects: 20
Study: 20231651

Group type: EXPERIMENTAL
Intervention: 6-alternative forced choice (6-AFC) test
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: 3-alternative forced choice (3-AFC) test
Number of subjects: 238